Over ten years experience with recombinant DNA technology and cell culture engineering applied in biotechnology, medicine and research. Expertise:Developing model systems to study signaling pathways involved in cellular differentiation and pathological cell changes.Developing advanced cell culture techniques and protein expression systems for cell line development and discovery/production of biopharmaceuticals.Specialties: recombinant protein production, biochemical assays, cellular and genomic characterization, cell line development, transient and stable protein expression systems, antibodies, epigenetics, cell signaling, metabolic pathways, laboratory management, IP and R&D strategies, emerging technologies.
-
Director CmcMerus N.V.Amsterdam, Nh, Nl -
Associate Director CmcMerus N.V. Jan 2022 - PresentUtrecht, Utrecht, Nl
-
Project Manager CmcMerus N.V. Nov 2017 - Dec 2021Utrecht, Utrecht, Nl
-
Translational ScientistCancer Research Uk (Cruk) Jun 2014 - Oct 2017London, GbThe Biotherapeutics Development Unit (BDU) manufactures experimental biologicals such as therapeutic proteins, antibodies and stem cell based therapeutics for phase I and II clinical trials in the UK. My role within the BDU is to evaluate and implement new technologies that enhance the transfer of novel biological drugs into GMP manufacturing and liaise with academia to accelerate the transition of anti-cancer therapies from the lab into the clinic. -
Senior ScientistCellagenics 2007 - 2013STEP technology: Novel strategies to improve the production of therapeutic proteins.CellaGenics developed a novel expression technology for the production of therapeutic antibodies and proteins in mammalian cell lines. In comparison with conventional strategies, the CellaGenics technology is a highly efficient method to obtain recombinant cell lines with substantial higher yields and without the need to screen large numbers of candidate cell lines. As of May 2013, Batavia Bioservices has been granted the exclusive license to the STEP technology.
-
ScientistCrucell 2005 - 2007STAR-technology.: Employing epigenetics to enhance the industrial production of therapeutic proteinsThe production of therapeutic proteins in mammalian cell lines is an inefficient process due to epigenetic gene silencing of the transgene that encodes for the therapeutic protein. It is therefore that STAR elements, which counteract chromatin-associated repression, were applied to improve the production of therapeutic proteins in mammalian cell lines. -
Postdoctoral Research AssociateHubrecht Institute, Developmental Biology And Stem Cell Research 2002 - 2004Utrecht, Nl
John Verhees Skills
John Verhees Education Details
-
Wageningen University & ResearchPlant Physiology -
Wageningen University & ResearchCell/Cellular And Molecular Biology
Frequently Asked Questions about John Verhees
What company does John Verhees work for?
John Verhees works for Merus N.v.
What is John Verhees's role at the current company?
John Verhees's current role is Director CMC.
What schools did John Verhees attend?
John Verhees attended Wageningen University & Research, Wageningen University & Research.
What skills is John Verhees known for?
John Verhees has skills like Biopharmaceuticals, Recombinant Dna Technology, Cell Biology, Molecular Biology, Flow Cytometry, Immunoassays, Cell Culture, Epigenetics, Gene Expression, Cell Lines, Intellectual Property, Spin Offs.
Who are John Verhees's colleagues?
John Verhees's colleagues are Sabien Drost-Schipper, Sally Hill, Edie Wu, David De Gorter, Cristina Bueno Díaz, Phd, Thomas Hero Haak, Maxine Gowen.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial